September 14, 2009 (Durham, North Carolina) — Patients taking dronedarone (Multaq, Sanofi-Aventis) for prevention of recurrent atrial fibrillation (AF) are about half as likely to remain in sinus ...
Although the absolute risk is small, amiodarone-treated patients run a higher relative risk of developing optic neuropathy compared with nontreated patients, especially males and also possibly those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results